The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer.
DDR
Ovarian cancer
PARPi resistance
platinum resistance
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
12
2022
revised:
16
04
2023
accepted:
29
05
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase inhibitor (PARPi). Responses to first-line treatment are frequent. For many patients, however, responses are suboptimal or short-lived. Over the last several years, multiple new classes of agents targeting DNA damage response (DDR) mechanisms have advanced through clinical development. In this review, we explore the preclinical rationale for the use of ATR inhibitors, CHK1 inhibitors, and WEE1 inhibitors, emphasizing their application to chemotherapy-resistant and PARPi-resistant ovarian cancer. We also present an overview of the clinical development of the leading drugs in each of these classes, emphasizing the rationale for monotherapy and combination therapy approaches.
Identifiants
pubmed: 37457127
doi: 10.20517/cdr.2022.146
pmc: PMC10344720
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
345-357Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
All authors declared that there are no conflicts of interest.
Références
Mol Cancer Ther. 2021 Jun;20(6):1092-1101
pubmed: 33785648
Mol Cell. 2005 Sep 2;19(5):607-18
pubmed: 16137618
Clin Cancer Res. 2021 Sep 1;27(17):4710-4716
pubmed: 34131002
Cancer Biol Ther. 2010 Apr 1;9(7):514-22
pubmed: 20107315
Clin Cancer Res. 2011 May 1;17(9):2799-806
pubmed: 21389100
Int J Gynecol Cancer. 2020 Aug;30(8):1224-1238
pubmed: 32571890
J Clin Oncol. 2016 May 20;34(15):1764-71
pubmed: 27044938
JCI Insight. 2017 Jan 12;2(1):e89760
pubmed: 28097235
Clin Cancer Res. 2022 Jan 1;28(1):36-44
pubmed: 34645648
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32369446
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Target Oncol. 2021 Sep;16(5):569-589
pubmed: 34559360
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Clin Cancer Res. 2020 Sep 15;26(18):4767-4776
pubmed: 32611648
Clin Cancer Res. 2017 Nov 1;23(21):6708-6720
pubmed: 28765325
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Semin Cancer Biol. 2021 Dec;77:99-109
pubmed: 34418576
Cancer Res. 2021 May 15;81(10):2774-2787
pubmed: 33514515
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Cancers (Basel). 2017 Apr 27;9(5):
pubmed: 28448462
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Cancer Lett. 2021 Jan 28;497:202-211
pubmed: 32991949
Mol Cancer Ther. 2009 Nov;8(11):2992-3000
pubmed: 19887545
Oncogenesis. 2022 Jun 18;11(1):33
pubmed: 35717336
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Cancer Chemother Pharmacol. 2020 Jan;85(1):9-20
pubmed: 31512029
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188633
pubmed: 34619333
Int J Mol Sci. 2022 Feb 01;23(3):
pubmed: 35163621
Cancer Discov. 2012 Jun;2(6):524-39
pubmed: 22628408
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Clin Cancer Res. 2019 Oct 15;25(20):6127-6140
pubmed: 31409614
Science. 2003 Jun 6;300(5625):1542-8
pubmed: 12791985
Oncotarget. 2016 Nov 1;7(44):71660-71672
pubmed: 27690219
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560564
Nat Commun. 2021 Sep 22;12(1):5574
pubmed: 34552099
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6
pubmed: 17626182
Oncogene. 2013 Jan 31;32(5):577-88
pubmed: 22430210
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
Mol Cell. 2013 Dec 12;52(5):758-66
pubmed: 24268576
DNA Repair (Amst). 2018 Nov;71:172-176
pubmed: 30177437
J Biol Chem. 2008 Jun 20;283(25):17250-9
pubmed: 18448427
Oncol Lett. 2017 Sep;14(3):3580-3586
pubmed: 28927115
Int J Oncol. 2021 Nov;59(5):
pubmed: 34558640
Genes Dev. 2017 Feb 1;31(3):318-332
pubmed: 28242626
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
Expert Opin Investig Drugs. 2019 Dec;28(12):1095-1100
pubmed: 31783714
Nature. 2009 Oct 22;461(7267):1071-8
pubmed: 19847258
Cell Cycle. 2009 Feb 1;8(3):482-9
pubmed: 19177015
Genes (Basel). 2022 Jun 20;13(6):
pubmed: 35741863
Cancers (Basel). 2022 Nov 24;14(23):
pubmed: 36497275
Lancet. 2021 Jan 23;397(10271):281-292
pubmed: 33485453
Gynecol Oncol. 2014 Oct;135(1):118-24
pubmed: 25093290
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Nat Rev Drug Discov. 2015 Jun;14(6):405-23
pubmed: 25953507
J Clin Oncol. 2016 Dec 20;34(36):4354-4361
pubmed: 27998224
Lancet Oncol. 2018 Feb;19(2):207-215
pubmed: 29361470
Mol Cancer Ther. 2015 Sep;14(9):2004-13
pubmed: 26141948
Cell Rep Med. 2021 Sep 23;2(9):100394
pubmed: 34622231
Acta Pharmacol Sin. 2017 Jul;38(7):1038-1047
pubmed: 28414200
Nature. 2015 Feb 12;518(7538):258-62
pubmed: 25642963
Int J Cancer. 2014 Mar 1;134(5):1013-23
pubmed: 23613359
Cell Death Differ. 2015 Jul;22(7):1144-57
pubmed: 25501596
Cancer Discov. 2018 Nov;8(11):1404-1421
pubmed: 30213835
Cell. 2011 Apr 29;145(3):435-46
pubmed: 21529715
Cancer Cell. 2019 Jun 10;35(6):851-867.e7
pubmed: 31185210
Mol Cell. 2003 Jan;11(1):203-13
pubmed: 12535533
Crit Rev Oncol Hematol. 2014 Feb;89(2):207-16
pubmed: 24071502
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Exp Clin Cancer Res. 2021 Jun 7;40(1):186
pubmed: 34099013
Mol Cell. 2010 Oct 22;40(2):179-204
pubmed: 20965415
Cell. 2023 May 25;186(11):2361-2379.e25
pubmed: 37192619
Diagnostics (Basel). 2020 May 05;10(5):
pubmed: 32380689
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Cancers (Basel). 2022 Jul 15;14(14):
pubmed: 35884498
Nat Commun. 2020 Jul 24;11(1):3726
pubmed: 32709856
Nat Commun. 2021 Jun 17;12(1):3636
pubmed: 34140467
Nat Cell Biol. 2005 Feb;7(2):195-201
pubmed: 15665856
Cancers (Basel). 2019 Oct 29;11(11):
pubmed: 31671803
Cancers (Basel). 2019 Jan 20;11(1):
pubmed: 30669514
Gynecol Oncol. 2021 Nov;163(2):246-253
pubmed: 34620496
Nat Rev Cancer. 2021 Jan;21(1):37-50
pubmed: 33128031
J Clin Oncol. 2016 Dec 20;34(36):4371-4380
pubmed: 27601554
Mol Cancer Res. 2019 Feb;17(2):431-445
pubmed: 30401718
NPJ Breast Cancer. 2019 Apr 15;5:14
pubmed: 30993195
Science. 1996 Jan 19;271(5247):353-6
pubmed: 8553071
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Clin Cancer Res. 2022 Nov 1;28(21):4724-4736
pubmed: 35929986